Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Pancreatic Neoplasms: HELP
Articles by Fabio Francesco Di Mola
Based on 9 articles published since 2010
(Why 9 articles?)
||||

Between 2010 and 2020, F. Francesco di Mola wrote the following 9 articles about Pancreatic Neoplasms.
 
+ Citations + Abstracts
1 Review Borderline resectable pancreatic cancer and the role of neoadjuvant chemoradiotherapy. 2016

di Sebastiano, Pierluigi / Grottola, Tommaso / di Mola, F Francesco. ·Division of Surgical Oncology, ASL-2 Abruzzo, "SS Annunziata" Hospital, 66100, Chieti, Italy. p.disebastiano@asl2abruzzo.it. · Division of Surgical Oncology, ASL-2 Abruzzo, "SS Annunziata" Hospital, 66100, Chieti, Italy. ·Updates Surg · Pubmed #27629483.

ABSTRACT: Borderline resectable pancreatic cancer is now recognized as a distinct clinical entity. In these cases, neoadjuvant treatment could maximize the potential for an R0 resection and avoid R1/R2 resections. In fact, by analyzing, the current literature is evident that approximately one-third of initially borderline resectable pancreatic tumors may undergo successful resection following neoadjuvant therapy. However, the enormous difficulties in achieving a consensus and the variability in therapeutic algorithms have delayed progress in establishing strong evidence-based practices for diagnosis and treatment. In addition, the absence of a unique definition of borderline resectable pancreatic cancer remains a great obstacle for planning a therapeutic strategy and surgical decision-making. If on the one hand, we can finally say that the presence of only few prospective trials generates no strong data to support a specific neoadjuvant therapy regimen in borderline resectable pancreatic cancer, on the other hand, there are many studies on patients with borderline resectable pancreatic cancer who receive neoadjuvant therapy that can enjoy an R0 resection with similar outcomes to up-front resectable disease.

2 Article Support Vector Machine Based on microRNA Expression Profiles to Predict Histological Origin of Ampullary Carcinoma: Case Report of a Patient Affected From Adenocarcinoma of the Papilla of Vater With Lynch Syndrome. 2016

Tavano, Francesca / Copetti, Massimiliano / Piepoli, Ada / Carella, Massimo / Gentile, Annamaria / Burbaci, Francesca Paola / Fontana, Andrea / De Bonis, Antonio / di Mola, Fabio Francesco / di Sebastiano, Pierluigi / Andriulli, Angelo. ·From the *Division of Gastroenterology and Research Laboratory, †Unit of Biostatistics, ‡Unit of Medical Genetics, §Department of Surgery, IRCCS "Casa Sollievo della Sofferenza" Hospital, San Giovanni Rotondo (FG); and ∥Division of Surgical Oncology, "SS Annunziata" Hospital, Chieti, Italy. ·Pancreas · Pubmed #26954494.

ABSTRACT: Adenocarcinomas of Vater's papilla (PVAC) may originate from either the pancreatic duct or the intestinal epithelium. Conflicting data have been reported about the frequency of the 2 anatomical entities and their influence on patients' prognosis. To ascertain the anatomical origin of PVAC in a family member of a Lynch syndrome kindred, we searched for microRNA (miRNA) expression profiles on resected tumor specimens. The support vector machine was trained on our previous miRNAs expression data sets of pancreatic and colorectal tissue samples and used to classify the site of origin of the tumor in our patient. The support vector machine worked by contrasting the profiles of miRNAs in patients with pancreatic ductal and colorectal cancers to that of our patient, which was finally classified as pancreatic ductal adenocarcinoma accordingly to alterations of 55 miRNAs. The PVAC might be originated from ductal epithelium rather than from the intestinal mucosa of the papilla in the case at issue. Alteration of miR-548b-3p, miR-551a, miR-21, miR-92a, miR-let-7i, and miR-181a* emerged as potentially associated with cancer genetic susceptibility in PVAC.

3 Article BAG3 promotes pancreatic ductal adenocarcinoma growth by activating stromal macrophages. 2015

Rosati, Alessandra / Basile, Anna / D'Auria, Raffaella / d'Avenia, Morena / De Marco, Margot / Falco, Antonia / Festa, Michelina / Guerriero, Luana / Iorio, Vittoria / Parente, Roberto / Pascale, Maria / Marzullo, Liberato / Franco, Renato / Arra, Claudio / Barbieri, Antonio / Rea, Domenica / Menichini, Giulio / Hahne, Michael / Bijlsma, Maarten / Barcaroli, Daniela / Sala, Gianluca / di Mola, Fabio Francesco / di Sebastiano, Pierluigi / Todoric, Jelena / Antonucci, Laura / Corvest, Vincent / Jawhari, Anass / Firpo, Matthew A / Tuveson, David A / Capunzo, Mario / Karin, Michael / De Laurenzi, Vincenzo / Turco, Maria Caterina. ·BIOUNIVERSA s.r.l., Fisciano, Salerno 84084, Italy. · Department of Medicine and Surgery, University of Salerno, Baronissi, Salerno 84081, Italy. · Department of Pharmacy, Division of Biomedicine "A. Leone", University of Salerno, Fisciano, Salerno 84084, Italy. · Pathology Unit, Istituto Nazionale Tumouri Fondazione "G. Pascale", Naples 81100, Italy. · Animal facility, Istituto Nazionale Tumouri Fondazione "G. Pascale", Naples 81100, Italy. · Reconstructive Microsurgery, Department of Oncology, Careggi University Hospital, Florence 50139, Italy. · Institut de Génétique Moléculaire de Montpellier, CNRS UMR5535, Montpellier 34293, France. · Laboratory for Experimental Oncology and Radiobiology, Academic Medical Center, University of Amsterdam, Amsterdam 1105AZ, The Netherlands. · Dipartimento di Scienze Mediche, Orali e Biotecnologiche, University "G. d'Annunzio" di Chieti-Pescara, Centro Studi sull'Invecchiamento, CeSI-MeT, Chieti 66100, Italy. · Division of Surgical Oncology, "S.S. Annunziata"Hospital, Chieti 66100, Italy. · Laboratory of Gene Regulation and Signal Transduction, Departments of Pharmacology and Pathology, UCSD, School of Medicine, San Diego, California 92093-0723, USA. · CALIXAR, Bioparc, Bâtiment Laënnec, Lyon 69008, France. · Department of Surgery, Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, Utah 84132, USA. · Cold Spring Harbor Laboratory, Cold Spring Harbor, New York 11724, USA. ·Nat Commun · Pubmed #26522614.

ABSTRACT: The incidence and death rate of pancreatic ductal adenocarcinoma (PDAC) have increased in recent years, therefore the identification of novel targets for treatment is extremely important. Interactions between cancer and stromal cells are critically involved in tumour formation and development of metastasis. Here we report that PDAC cells secrete BAG3, which binds and activates macrophages, inducing their activation and the secretion of PDAC supporting factors. We also identify IFITM-2 as a BAG3 receptor and show that it signals through PI3K and the p38 MAPK pathways. Finally, we show that the use of an anti-BAG3 antibody results in reduced tumour growth and prevents metastasis formation in three different mouse models. In conclusion, we identify a paracrine loop involved in PDAC growth and metastatic spreading, and show that an anti-BAG3 antibody has therapeutic potential.

4 Article SIRT1 and circadian gene expression in pancreatic ductal adenocarcinoma: Effect of starvation. 2015

Tavano, Francesca / Pazienza, Valerio / Fontana, Andrea / Burbaci, Francesca Paola / Panebianco, Concita / Saracino, Chiara / Lombardi, Lucia / De Bonis, Antonio / di Mola, Fabio Francesco / di Sebastiano, Pierluigi / Piepoli, Ada / Vinciguerra, Manlio / Fracavilla, Massimo / Giuliani, Francesco / Rubino, Rosa / Andriulli, Angelo / Mazzoccoli, Gianluigi. ·Division of Gastroenterology, IRCCS Scientific Institute and Regional General Hospital "Casa Sollievo della Sofferenza" , San Giovanni Rotondo (FG) , Italy . ·Chronobiol Int · Pubmed #25798752.

ABSTRACT: Pancreatic cancer (PC), the fourth leading cause of cancer-related deaths, is characterized by high aggressiveness and resistance to chemotherapy. Pancreatic carcinogenesis is kept going by derangement of essential cell processes, such as proliferation, apoptosis, metabolism and autophagy, characterized by rhythmic variations with 24-h periodicity driven by the biological clock. We assessed the expression of the circadian genes ARNLT, ARNLT2, CLOCK, PER1, PER2, PER3, CRY1, CRY2 and the starvation-activated histone/protein deacetylase SIRT1 in 34 matched tumor and non-tumor tissue specimens of PC patients, and evaluated in PC derived cell lines if the modulation of SIRT1 expression through starvation could influence the temporal pattern of expression of the circadian genes. We found a significant down-regulation of ARNLT (p = 0.015), CRY1 (p = 0.013), CRY2 (p = 0.001), PER1 (p < 0.0001), PER2 (p < 0.001), PER3 (p = 0.001) and SIRT1 (p = 0.017) in PC specimens. PER3 and CRY2 expression levels were lower in patients with jaundice at diagnosis ( < 0.05). Having adjusted for age, adjuvant therapy and tumor stage, we evidenced that patients with higher PER2 and lower SIRT1 expression levels showed lower mortality (p = 0.028). Levels and temporal patterns of expression of many circadian genes and SIRT1 significantly changed upon serum starvation in vitro, with differences among four different PC cell lines examined (BXPC3, CFPAC, MIA-PaCa-2 and PANC-1). Serum deprivation induced changes of the overall mean level of the wave and amplitude, lengthened or shortened the cycle time and phase-advanced or phase-delayed the rhythmic oscillation depending on the gene and the PC cell line examined. In conclusion, a severe deregulation of expression of SIRT1 and circadian genes was evidenced in the cancer specimens of PC patients, and starvation influenced gene expression in PC cell lines, suggesting that the altered interplay between SIRT1 and the core circadian proteins could represent a crucial player in the process of pancreatic carcinogenesis.

5 Article Modeling interactions between Human Equilibrative Nucleoside Transporter-1 and other factors involved in the response to gemcitabine treatment to predict clinical outcomes in pancreatic ductal adenocarcinoma patients. 2014

Tavano, Francesca / Fontana, Andrea / Pellegrini, Fabio / Burbaci, Francesca Paola / Rappa, Francesca / Cappello, Francesco / Copetti, Massimiliano / Maiello, Evaristo / Lombardi, Lucia / Graziano, Paolo / Vinciguerra, Manlio / di Mola, Fabio Francesco / di Sebastiano, Pierluigi / Andriulli, Angelo / Pazienza, Valerio. · ·J Transl Med · Pubmed #25199538.

ABSTRACT: BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is an extremely aggressive malignancy, characterized by largely unsatisfactory responses to the currently available therapeutic strategies. In this study we evaluated the expression of genes involved in gemcitabine uptake in a selected cohort of patients with PDAC, with well-defined clinical-pathological features. METHODS: mRNA levels of hENT1, CHOP, MRP1 and DCK were evaluated by means of qRT-PCR in matched pairs of tumor and adjacent normal tissue samples collected from PDAC patients treated with gemcitabine after surgical tumor resection. To detect possible interaction between gene expression levels and to identify subgroups of patients at different mortality/progression risk, the RECursive Partitioning and Amalgamation (RECPAM) method was used. RESULTS: RECPAM analysis showed that DCK and CHOP were most relevant variables for the identification of patients with different mortality risk, while hENT1 and CHOP were able to identify subgroups of patients with different disease progression risk. CONCLUSION: hENT1, CHOP, MRP1 and DCK appear correlated to PDAC, and this interaction might influence disease behavior.

6 Article Influence of preoperative biliary drainage on surgical outcome after pancreaticoduodenectomy: single centre experience. 2014

di Mola, F Francesco / Tavano, Francesca / Rago, R Rita / De Bonis, Antonio / Valvano, M Rosa / Andriulli, Angelo / di Sebastiano, Pierluigi. ·Division of Surgical Oncology, "SS Annunziata" Hospital, 66100, Chieti, Italy. ·Langenbecks Arch Surg · Pubmed #24682374.

ABSTRACT: PURPOSE: Controversy prevails on the impact of preoperative biliary drainage (PBD) on postoperative complications and clinical outcome of pancreatic cancer. We determined whether PBD is associated with increased morbidity and mortality rates after pancreaticoduodenectomy. METHODS: A total of 131 consecutive patients who underwent pancreaticoduodenectomy (93 jaundiced, 38 with no jaundice) were included in this study. Overall, 57 % of jaundiced patients underwent PBD, while 43 % were not drained. The impact of PBD on postoperative morbidity and mortality was evaluated by means of logistic regression analysis. The Kaplan-Meier method was applied to determine the effect of PBD on survival of patients with malignant lesions. RESULTS: Mortality and morbidity rate was 3 % and 54.6 %, respectively. PBD was demonstrated to be the unique predictor of complications (odds ration [OR] = 10.18; 95 % confidence interval [CI], 3.65-28.39, p < 0.001). The jaundiced patients who were drained exhibited high frequencies of wound infection (p < 0.001), post-pancreatectomy haemorrhage (p = 0.0185) and hyperglycaemia (p < 0.001). In addition, an increased frequency of pancreatic fistula emerged among drained patients compared to those who were not drained (p = 0.036). PBD did not affect survival of patient with malignant lesions. CONCLUSIONS: With the exception of the classical indications, PBD should be carefully evaluated in patients with resectable pancreatic cancer.

7 Article Expression of the antiapoptotic protein BAG3 is a feature of pancreatic adenocarcinoma and its overexpression is associated with poorer survival. 2012

Rosati, Alessandra / Bersani, Samantha / Tavano, Francesca / Dalla Pozza, Elisa / De Marco, Margot / Palmieri, Marta / De Laurenzi, Vincenzo / Franco, Renato / Scognamiglio, Giosuè / Palaia, Raffaele / Fontana, Andrea / di Sebastiano, Pierluigi / Donadelli, Massimo / Dando, Ilaria / Medema, Jan Paul / Dijk, Frederike / Welling, Lieke / di Mola, Fabio Francesco / Pezzilli, Raffaele / Turco, Maria Caterina / Scarpa, Aldo. ·Department of Pharmaceutical and Biomedical Sciences, University of Salerno, Fisciano, Italy. ·Am J Pathol · Pubmed #22944597.

ABSTRACT: Pancreatic ductal adenocarcinoma (PDAC) is one of the most deadly cancers, being the fourth leading cause of cancer-related deaths. Long-term survival reaching 15% is achieved in less than 5% of patients who undergo surgery, and median survival is only 6 months in those with inoperable lesions. A deeper understanding of PDAC biologic characteristics as well as novel prognostic markers are therefore required to improve outcomes. Herein we report that BAG3, a protein with recognized anti-apoptotic activity, was expressed in 346 PDACs analyzed, but was not expressed in the surrounding nonneoplastic tissue. In a cohort of 66 patients who underwent radical resection (R0), survival was significantly shorter in patients with high BAG3 expression (median, 12 months) than in those with low BAG3 expression (median, 23 months) (P = 0.001). Furthermore, we report that BAG3 expression in PDAC-derived cell lines protects from apoptosis and confers resistance to gemcitabine, offering a partial explanation for the survival data. Our results indicate that BAG3 has a relevant role in PDAC biology, and suggest that BAG3 expression level might be a potential marker for prediction of patient outcome.

8 Article A modified fast-track program for pancreatic surgery: a prospective single-center experience. 2011

di Sebastiano, Pierluigi / Festa, Leonardina / De Bonis, Antonio / Ciuffreda, Andrea / Valvano, Maria Rosa / Andriulli, Angelo / di Mola, F Francesco. ·Department of Surgery, IRCCS-Casa Sollievo della Sofferenza Hospital, San Giovanni Rotondo, Italy. p.disebastiano@operapadrepio.it ·Langenbecks Arch Surg · Pubmed #20703500.

ABSTRACT: OBJECTIVE: The objective of this study is to evaluate the impact of a fast-track protocol in a high-volume center for patients with pancreatic disorders. BACKGROUND: The concept of fast-track surgery allowing accelerated postoperative recovery is accepted in colorectal surgery, but efficacy data are only preliminary for patients undergoing major pancreatic surgery. We aimed to evaluate the impact of a modified fast-track protocol in a high-volume center for patients with pancreatic disorders. METHODS: Between February 2005 and January 2010, 145 subjects had resective pancreatic surgery and were enrolled in the program. Essential features of the program were no preanaesthetic medication, upper and lower air-warming device, avoidance of excessive i.v. fluids perioperatively, effective control of pain, early reinstitution of oral feeding, and immediate mobilization and restoration of bowel function following surgery. Outcome measures were postoperative complications such as pancreatic fistula, delayed gastric emptying, biliary leak, intra-abdominal abscess, post-pancreatectomy hemorrhage, acute pancreatitis, wound infection, 30-day mortality, postoperative hospital stay, and readmission rates. RESULTS: On average, patients were discharged on postoperative day 10 (range 6-69), with a 30-day readmission rate of 6.2%. Percentage of patients with at least one complication was 38.6%. Pancreatic anastomotic leakage occurred in seven of 101 pancreatico-jejunostomies, and biliary leak in three of 109 biliary jejunostomies. Postoperative hemorrhage occurred in ten (6.9%) patients and wound infection in nine (6.2%) cases. In-hospital mortality was 2.7%. Fast-track parameters, such as normal food and first stool, correlated significantly with early discharge (<0.05). At multivariate analysis, lack of jaundice, and resumption of normal diet by the 5th postoperative day were independent factors of early discharge. CONCLUSION: Fast-track programs are feasible, easy, and also applicable for patients undergoing a major surgery such as pancreatic resection.

9 Minor BAG3 is a novel serum biomarker for pancreatic adenocarcinomas. 2013

Falco, Antonia / Rosati, Alessandra / Festa, Michelina / Basile, Anna / De Marco, Margot / d'Avenia, Morena / Pascale, Maria / Dal Piaz, Fabrizio / Tavano, Francesca / Di Mola, Fabio Francesco / di Sebastiano, Pierluigi / Berloco, Pasquale Bartolomeo / Nudo, Francesco / Caraglia, Michele / Febbraro, Antonio / Barcaroli, Daniela / Scarpa, Aldo / Pezzilli, Raffaele / De Laurenzi, Vincenzo / Turco, Maria Caterina. · ·Am J Gastroenterol · Pubmed #23821002.

ABSTRACT: -- No abstract --